Biotrial

Unlocking the mysteries of molecules!  Biotrial's Bioanalysis team is pioneering innovative methods in 80% of our studies, using LC-MS/MS and diverse biofluids to analyze drugs, metabolites, and more. 👇Explore the infographic to see how we're driving scientific progress. #Bioanalysis #Bioanalytical 

Biotrial is proud to have contributed to a groundbreaking preclinical study published in PLOS ONE! The study, titled "Afatinib or Bevacizumab in combination with Osimertinib efficiently controls tumor development in orthotopic murine models of non-small lung cancer," is a result of a successful collaborative project through our common laboratory #Oncotrial with Remy Pedeux's team (OSS U1242) and Ulrich Jarry. This research highlights effective new therapies for EGFR-mutated lung cancer using advanced mouse models. A big thank you to all the partners involved! 👉 Download the study: https://lnkd.in/g4T58_dB #Oncotrial #Lungcancerresearch #Preclinicalstudy 

Biotrial’s CNS Breakfast Series Wrap-Up! We recently hosted three breakfast events focusing on "Translational Strategies for Successful Early CNS Drug Development." These events, led by Florian ADRAOUI and Mathieu Grace, Preclinical and Core Lab experts, gathered industry leaders for insightful discussions on key CNS drug development topics. 👉 Read the full article to learn more and stay updated on upcoming events: https://lnkd.in/egux5gqE #CNS #drugdevelopment #translationalresearch

Enhanced Preclinical EEG methods and new cognitive ERPs at Biotrial We're excited to announce enhancements to Biotrial’s preclinical EEG methods, designed to deliver increased sensitivity and introduce new cognitive event-related potentials (ERPs). These advancements include updating our equipment to evaluate new parameters and obtain more robust data on EEG biomarkers already available such as the gamma-band ASSR. Among the new EEG biomarkers in development, Biotrial is working on a new auditory ERP assessing auditory gating, which is crucial for evaluating cognitive and attentional functions through EEG. #EEG #neurosciences #preclinical

Biotrial and Quince Therapeutics celebrate the inclusion of the first patient dosed in phase 3 clinical trial of EryDex for the treatment of Ataxia-Telangiectasia. This significant milestone brings us one step closer to advancing treatment for this rare disease. Expertise in Phase III trials drives our commitment to better healthcare. 👉 To know more: https://lnkd.in/gnnh_He2  #ATAXIA #pediatricresearch #PhaseIII 

We are pleased to announce that Benoit Baron, Head of Data Management Development and Service Solutions at Biotrial, has achieved a new certification: Medidata Rave RTSM Trial Supply Management (2024) from Medidata Solutions! Congratulations Benoit! At Biotrial, we are committed to continuous learning and skill acquisition, continually enhancing our expertise. We are proud to share that the entire Biometrics team is accredited to perform RTSM setups. This certification reflects the quality and dedication of our team's work on all studies. #MedidataRaveRTSM #Trialsupplymanagement

Biotrial and our experts would like to thank everyone who joined us at the 7th annual Digital Biomarkers in Clinical Trials Summit in Switzerland. Julie Remy, Philippe L'HOSTIS, Zoé Liermannand Damien MAURICE had a great time discussing the latest trends and ways to improve patient experience and collect better data using digital health tools. #digitalbiomarkers #clinicaltrials #patientoutcomes

Biotrial's experts KARINE PROVOST and Vincent D. participated in the GUF CDISC conference in Paris, exploring the latest advancements in clinical data standards. A big thank you to everyone who stopped by to chat with our team. #Cdisc #datamanagement

Biotrial is proud to support MIRA Pharmaceuticals in their innovative #preclinical study of Ketamir-2, a novel oral ketamine analog. This pioneering treatment has demonstrated promising results for both depression and treatment-resistant depression (TRD), offering enhanced safety and efficacy compared to traditional ketamine. We look forward to support future preclinical and clinical trials and continuing to contribute to advancements in #neuropsychiatric treatments. 👉 Learn more about the study: https://lnkd.in/e4yWhW-U

Wrapping Up PSI 2024! Biotrial extends a heartfelt thank you to everyone who joined us at the PSI 2024 Conference in Amsterdam. It was an incredible opportunity to connect, share insights, and explore the future of statistics in drug development. Our experts Stephanie Le Goaller and Rob Pluske, enjoyed engaging with you and discussing the latest trends in Biostatistics. Stay tuned for more exciting developments in our journey! #PSI2024 #Statistics